RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 MPACT Trial: SPARC Not Predictive or Prognostic in Pancreatic Cancer
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 22
SP 11
OP 11
DO 10.1177/155989771422006
UL http://mdc.sagepub.com/content/14/22/11.abstract
AB Secreted protein acidic and rich in cysteine (SPARC) protein expression levels were not associated with overall survival (OS) or progression-free survival (PFS) in patients with metastatic pancreatic cancer from the Phase 3 Study of ABI-007 (Albumin-Bound Paclitaxel) plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas trial [MPACT; Hidalgo M et al. Ann Oncol 2014 (abstr O-0003)]. This article presents data from a subanalysis of the MPACT trial.